Log in

ASX:PTXPrescient Therapeutics Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/13/2020)
Today's Range
Now: A$0.04
50-Day Range
MA: A$0.04
52-Week Range
Now: A$0.04
Volume537,831 shs
Average VolumeN/A
Market Capitalization$17.35 million
P/E RatioN/A
Dividend YieldN/A
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 9692 7222



Sales & Book Value

Annual Sales$1.54 million
Cash FlowA$0.02 per share
Book ValueA$0.03 per share



Market Cap$17.35 million
Next Earnings DateN/A

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter.

Prescient Therapeutics (ASX:PTX) Frequently Asked Questions

How has Prescient Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Prescient Therapeutics' stock was trading at A$0.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PTX shares have increased by 25.7% and is now trading at A$0.04. View which stocks have been most impacted by Coronavirus.

Has Prescient Therapeutics been receiving favorable news coverage?

News stories about PTX stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Prescient Therapeutics earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Prescient Therapeutics.

Who are some of Prescient Therapeutics' key competitors?

What other stocks do shareholders of Prescient Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prescient Therapeutics investors own include SKYCITY Entertainment Group (SKC) and Finders Resources (FND).

Who are Prescient Therapeutics' key executives?

Prescient Therapeutics' management team includes the following people:
  • Mr. Yatomi-Clarke Steven Lee, MD, CEO & Director
  • Prof. Said M. Sebti M.D., Chief Scientific Officer
  • Dr. Terrence G. Chew M.D., R.A.C., Chief Medical Officer (Age 72)
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Company Sec. (Age 46)
  • Dr. Claudia Gregorio-King, VP of Operations

What is Prescient Therapeutics' stock symbol?

Prescient Therapeutics trades on the ASX under the ticker symbol "PTX."

What is Prescient Therapeutics' stock price today?

One share of PTX stock can currently be purchased for approximately A$0.04.

How big of a company is Prescient Therapeutics?

Prescient Therapeutics has a market capitalization of $17.35 million and generates $1.54 million in revenue each year.

What is Prescient Therapeutics' official website?

The official website for Prescient Therapeutics is www.ptxtherapeutics.com.

How can I contact Prescient Therapeutics?

The company can be reached via phone at 61 3 9692 7222.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.